


## LLY-283

<b>Cat. No.:</b>	HY-107777		
<b>CAS No.:</b>	2040291-27-6		
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>18</sub> N <sub>4</sub> O <sub>4</sub>		
<b>Molecular Weight:</b>	342.35		
<b>Target:</b>	Histone Methyltransferase		
<b>Pathway:</b>	Epigenetics		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 125 mg/mL (365.12 mM; Need ultrasonic)  
 H<sub>2</sub>O : 3.57 mg/mL (10.43 mM; ultrasonic and warming and heat to 60°C)

	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.9210 mL	14.6049 mL	29.2099 mL
	5 mM	0.5842 mL	2.9210 mL	5.8420 mL
	10 mM	0.2921 mL	1.4605 mL	2.9210 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility: ≥ 2.08 mg/mL (6.08 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
 Solubility: ≥ 2.08 mg/mL (6.08 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
 Solubility: ≥ 2.08 mg/mL (6.08 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

LLY-283 is a potent, selective and oral protein arginine methyltransferase 5 (PRMT5) inhibitor, with an IC<sub>50</sub> of 22 nM and a K<sub>D</sub> of 6 nM for PRMT5:MEP50 complex, and shows antitumor activity.

#### IC<sub>50</sub> & Target

PRMT5

#### In Vitro

LLY-283 is a potent, oral and selective arginine methyltransferase 5 (PRMT5) inhibitor, with an IC<sub>50</sub> of 22 nM in vitro and 25

nM in cells, as well as a  $K_d$  of 6 nM for PRMT5:MEP50 complex in vitro; LLY-283 inhibits the proliferation of A375 cell with an  $IC_{50}$  of 46 nM<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

LLY-283 (20 mg/kg; p.o., QD (once a day)) causes a significant inhibition on tumor growth in mice bearing A375 cells after treatment for 28 days<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Nat Commun. 2023 Jan 6;14(1):97.
- Neurosci Lett. 2022 Mar 9;136576.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Zahid Q. Bonday, et al. LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity. ACS Med. Chem. Lett., 2018, 9 (7), pp 612-617.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA